AA 是一种罕见的胃肠道癌症，发病率低，每 10 万人中约有 1.3 人发病，且属于罕见病范畴，目前尚无 FDA 批准的特效疗法。标准治疗方案为细胞减灭术联合腹腔热灌注化疗（CRS + HIPEC），但并非所有患者都适合手术。传统观念认为 AA 对全身化疗反应不佳，不过近年来，靶向治疗、免疫治疗和腹腔内定向治疗展现出一定潜力。

恩考拉非尼、西妥昔单抗和 mFOLFOX6 的组合疗法已获得 FDA 的加速批准，用于治疗患有 BRAF V600E 突变的转移性结直肠癌患者。 美国食品药品监督管理局（FDA）加速批准恩科拉非尼（Braftovi，辉瑞公司子公司 Array ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full ...

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer last month, and it already has survival data that could see that converted ...

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study.

A new research paper was published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low ...

Treatment with Tafinlar in combination with Mekinist showed what researchers described as “considerable efficacy” among ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...